Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.125 CAD | +13.64% | +13.64% | +92.31% |
Valuation
Fiscal Period: August | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Capitalization 1 | 6.884 | 6.155 | 44.79 | 16.75 | 12.71 | 2.603 |
Enterprise Value (EV) 1 | 5.633 | 5.947 | 38.67 | 14.34 | 11.3 | 2.478 |
P/E ratio | -7.21 x | -3.06 x | -3.4 x | -2.01 x | -1.55 x | -0.37 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - | - |
EV / Revenue | - | - | - | - | - | - |
EV / EBITDA | -6.56 x | -3.37 x | -4.58 x | - | -1.98 x | -0.5 x |
EV / FCF | -23.2 x | -6.77 x | -38.4 x | -3.06 x | -19 x | -5.06 x |
FCF Yield | -4.31% | -14.8% | -2.6% | -32.7% | -5.27% | -19.8% |
Price to Book | 5.09 x | 1.24 x | 3.74 x | 1.84 x | 2.26 x | 1.77 x |
Nbr of stocks (in thousands) | 1,147 | 1,894 | 5,429 | 6,699 | 9,432 | 15,776 |
Reference price 2 | 6.000 | 3.250 | 8.250 | 2.500 | 1.348 | 0.1650 |
Announcement Date | 14/12/18 | 18/12/19 | 18/12/20 | 26/11/21 | 25/11/22 | 29/12/23 |
Income Statement Evolution (Annual data)
Fiscal Period: August | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net sales | - | - | - | - | - | - |
EBITDA 1 | -0.8582 | -1.766 | -8.44 | - | -5.708 | -4.981 |
EBIT 1 | -0.8991 | -1.793 | -8.467 | -7.878 | -5.743 | -5.032 |
Operating Margin | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -0.9376 | -1.896 | -8.538 | -7.734 | -6.054 | -6.781 |
Net income 1 | -0.9376 | -1.896 | -8.538 | -7.734 | -6.054 | -6.781 |
Net margin | - | - | - | - | - | - |
EPS 2 | -0.8322 | -1.061 | -2.423 | -1.241 | -0.8708 | -0.4477 |
Free Cash Flow 1 | -0.2429 | -0.8785 | -1.007 | -4.687 | -0.595 | -0.4897 |
FCF margin | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 14/12/18 | 18/12/19 | 18/12/20 | 26/11/21 | 25/11/22 | 29/12/23 |
Income Statement Evolution (Quarterly data)
Fiscal Period: August | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 |
---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - |
EBITDA | - | - | - | - | - |
EBIT | - | - | - | - | - |
Operating Margin | - | - | - | - | - |
Earnings before Tax (EBT) | - | - | - | - | - |
Net income | -1.836 | - | - | - | - |
Net margin | - | - | - | - | - |
EPS | -0.2750 | - | - | - | - |
Dividend per Share | - | - | - | - | - |
Announcement Date | 27/04/22 | 29/07/22 | 26/11/22 | 30/01/23 | 01/05/23 |
Balance Sheet Analysis
Fiscal Period: August | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | - |
Net Cash position 1 | 1.25 | 0.21 | 6.12 | 2.41 | 1.41 | 0.13 |
Leverage (Debt/EBITDA) | - | - | - | - | - | - |
Free Cash Flow 1 | -0.24 | -0.88 | -1.01 | -4.69 | -0.6 | -0.49 |
ROE (net income / shareholders' equity) | -63.5% | -59.8% | -99.3% | -72.5% | -82.1% | -191% |
ROA (Net income/ Total Assets) | -36.7% | -33.2% | -58.3% | -42.9% | -39.3% | -51% |
Assets 1 | 2.552 | 5.717 | 14.65 | 18.03 | 15.41 | 13.3 |
Book Value Per Share 2 | 1.180 | 2.630 | 2.210 | 1.360 | 0.6000 | 0.0900 |
Cash Flow per Share 2 | 1.080 | 0.1100 | 1.110 | 0.3600 | 0.1500 | 0.0100 |
Capex | - | - | - | - | - | - |
Capex / Sales | - | - | - | - | - | - |
Announcement Date | 14/12/18 | 18/12/19 | 18/12/20 | 26/11/21 | 25/11/22 | 29/12/23 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+92.31% | 1.98M | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- AGN Stock
- Financials Algernon Pharmaceuticals Inc.